KR20240117556A - 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 - Google Patents
유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20240117556A KR20240117556A KR1020247018882A KR20247018882A KR20240117556A KR 20240117556 A KR20240117556 A KR 20240117556A KR 1020247018882 A KR1020247018882 A KR 1020247018882A KR 20247018882 A KR20247018882 A KR 20247018882A KR 20240117556 A KR20240117556 A KR 20240117556A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- alkyl
- heterocycloalkyl
- cycloalkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/130290 | 2021-11-12 | ||
| CN2021130290 | 2021-11-12 | ||
| CN2022123827 | 2022-10-08 | ||
| CNPCT/CN2022/123827 | 2022-10-08 | ||
| PCT/CN2022/131293 WO2023083286A1 (en) | 2021-11-12 | 2022-11-11 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240117556A true KR20240117556A (ko) | 2024-08-01 |
Family
ID=86335131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018882A Pending KR20240117556A (ko) | 2021-11-12 | 2022-11-11 | 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20250026754A1 (https=) |
| EP (1) | EP4430050A4 (https=) |
| JP (1) | JP2024543477A (https=) |
| KR (1) | KR20240117556A (https=) |
| CN (1) | CN119053601A (https=) |
| AR (1) | AR127646A1 (https=) |
| AU (1) | AU2022386486A1 (https=) |
| CA (1) | CA3235765A1 (https=) |
| CL (2) | CL2024001397A1 (https=) |
| CO (1) | CO2024006269A2 (https=) |
| CR (1) | CR20240191A (https=) |
| DO (1) | DOP2024000080A (https=) |
| GE (1) | GEAP202416532A (https=) |
| IL (1) | IL312642A (https=) |
| JO (1) | JOP20240096A1 (https=) |
| MX (1) | MX2024005755A (https=) |
| PE (1) | PE20241307A1 (https=) |
| TW (1) | TW202334142A (https=) |
| WO (1) | WO2023083286A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20240191A (es) | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| WO2024086790A1 (en) * | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| WO2025227060A1 (en) | 2024-04-26 | 2025-10-30 | Insilico Medicine Ip Limited | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE69921358T2 (de) * | 1998-12-23 | 2006-03-09 | Bristol-Myers Squibb Pharma Co. | Stickstoffhaltige heterobicyclen als faktor-xa-hemmer |
| MXPA03007623A (es) | 2001-02-26 | 2003-12-04 | Tanabe Seiyaku Co | Derivado de piridopirimidina o naftiridina. |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| ITFR20030005U1 (it) | 2003-03-17 | 2003-06-16 | C D R | Sistema di protezione solare (frangisole f1) |
| JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| EP2370437B1 (en) | 2008-11-25 | 2013-09-04 | Nerviano Medical Sciences S.r.l. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| SG10201407012XA (en) | 2009-10-29 | 2014-11-27 | Genosco | Kinase inhibitors |
| US8541418B2 (en) | 2009-12-23 | 2013-09-24 | Elan Pharmaceutical, Inc. | Inhibitors of polo-like kinase |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| AU2011376721B2 (en) | 2011-09-16 | 2017-06-08 | Sanofi | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| CA2896731A1 (en) | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CN104311555B (zh) | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | 吡唑并哌啶酮类化合物及其组合物及用途 |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US10189841B2 (en) * | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| EP3464286B1 (en) | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| WO2019089216A1 (en) | 2017-11-01 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| BR112021010715A2 (pt) * | 2018-12-20 | 2021-11-16 | Ksq Therapeutics Inc | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
| JP7553450B2 (ja) * | 2018-12-28 | 2024-09-18 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ１を阻害するための組成物 |
| CA3168009A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| EP4161494A4 (en) | 2020-06-02 | 2024-07-17 | KSQ Therapeutics, Inc. | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| TW202246255A (zh) | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
| US20240182481A1 (en) | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| AU2022238886A1 (en) | 2021-03-17 | 2023-09-14 | Medivir Ab | Purine derivatives as anticancer agents |
| WO2022199652A1 (en) | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| MX2023011709A (es) | 2021-04-07 | 2023-10-12 | Forma Therapeutics Inc | Inhibidor de la proteasa 1 especifica de ubiquitina (usp1). |
| EP4321515A4 (en) | 2021-04-09 | 2025-06-25 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR |
| EP4430041A4 (en) | 2021-11-12 | 2025-09-24 | Insilico Medicine Ip Ltd | SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES |
| CR20240191A (es) | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| GEAP202416531A (en) | 2021-11-12 | 2024-10-28 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
-
2022
- 2022-11-11 CR CR20240191A patent/CR20240191A/es unknown
- 2022-11-11 AU AU2022386486A patent/AU2022386486A1/en active Pending
- 2022-11-11 JP JP2024528452A patent/JP2024543477A/ja active Pending
- 2022-11-11 EP EP22892079.9A patent/EP4430050A4/en active Pending
- 2022-11-11 GE GEAP202416532A patent/GEAP202416532A/en unknown
- 2022-11-11 KR KR1020247018882A patent/KR20240117556A/ko active Pending
- 2022-11-11 CN CN202280087378.2A patent/CN119053601A/zh active Pending
- 2022-11-11 MX MX2024005755A patent/MX2024005755A/es unknown
- 2022-11-11 TW TW111143088A patent/TW202334142A/zh unknown
- 2022-11-11 PE PE2024001033A patent/PE20241307A1/es unknown
- 2022-11-11 AR ARP220103104A patent/AR127646A1/es unknown
- 2022-11-11 WO PCT/CN2022/131293 patent/WO2023083286A1/en not_active Ceased
- 2022-11-11 CA CA3235765A patent/CA3235765A1/en active Pending
- 2022-11-11 US US18/709,234 patent/US20250026754A1/en not_active Abandoned
- 2022-11-11 IL IL312642A patent/IL312642A/en unknown
-
2023
- 2023-02-06 US US18/106,339 patent/US11739077B2/en active Active
- 2023-06-26 US US18/340,978 patent/US12570634B2/en active Active
-
2024
- 2024-04-24 JO JOJO/P/2024/0096A patent/JOP20240096A1/ar unknown
- 2024-05-09 CL CL2024001397A patent/CL2024001397A1/es unknown
- 2024-05-10 DO DO2024000080A patent/DOP2024000080A/es unknown
- 2024-05-17 CO CONC2024/0006269A patent/CO2024006269A2/es unknown
-
2025
- 2025-04-09 CL CL2025001068A patent/CL2025001068A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202416532A (en) | 2024-08-12 |
| CL2025001068A1 (es) | 2025-07-11 |
| US20250026754A1 (en) | 2025-01-23 |
| US20240190839A1 (en) | 2024-06-13 |
| PE20241307A1 (es) | 2024-06-24 |
| MX2024005755A (es) | 2024-09-06 |
| CR20240191A (es) | 2024-09-13 |
| CL2024001397A1 (es) | 2024-10-25 |
| JOP20240096A1 (ar) | 2024-04-24 |
| AU2022386486A1 (en) | 2024-05-09 |
| EP4430050A4 (en) | 2025-09-24 |
| WO2023083286A1 (en) | 2023-05-19 |
| US11739077B2 (en) | 2023-08-29 |
| US12570634B2 (en) | 2026-03-10 |
| CN119053601A (zh) | 2024-11-29 |
| EP4430050A1 (en) | 2024-09-18 |
| TW202334142A (zh) | 2023-09-01 |
| CA3235765A1 (en) | 2023-05-19 |
| AR127646A1 (es) | 2024-02-14 |
| IL312642A (en) | 2024-07-01 |
| US20230183210A1 (en) | 2023-06-15 |
| JP2024543477A (ja) | 2024-11-21 |
| DOP2024000080A (es) | 2024-11-29 |
| CO2024006269A2 (es) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240117555A (ko) | 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 | |
| KR20240117556A (ko) | 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 | |
| KR20240101680A (ko) | 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 | |
| CN111757878B (zh) | 一种哒嗪类衍生物抑制剂、其制备方法和应用 | |
| WO2023114733A1 (en) | Kras modulators and uses thereof | |
| CN105473576B (zh) | 针对心脏病症的嘧啶二酮化合物 | |
| WO2022261210A1 (en) | Kras modulators and uses thereof | |
| TWI704149B (zh) | 抑制瞬態電位受器ａ１離子通道 | |
| WO2025049619A1 (en) | Kras modulators and uses thereof | |
| KR101921764B1 (ko) | 피라졸로-퀴놀린 | |
| CN117980305A (zh) | 表现出mnk抑制作用的螺环吡啶-1,5-二酮及其使用方法 | |
| CN114539229A (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| JPWO2003070730A1 (ja) | ピロロピリミジン誘導体 | |
| CN120530118A (zh) | 一种氮杂环烷烃化合物、药物组合物及其用途 | |
| TW202334157A (zh) | 一種Ｗｎｔ通路抑制劑化合物 | |
| OA21707A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| EA050901B1 (ru) | Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение | |
| OA21706A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| OA21708A (en) | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof. | |
| CA3235762A1 (en) | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof | |
| WO2024051795A1 (zh) | 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物 | |
| CN107759522A (zh) | 羧酸类衍生物、其制备方法及其在医药上的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |